Clinic
Uptown Providers PC
Uptown Providers PC was paid $2.18M by Medicaid between Sep 2019 and Dec 2024, across 40 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 36% of everything it billed.
33Billing provider infoUPTOWN PROVIDERS PC
OREGON CITY, OR 97045
OREGON CITY, OR 97045
33aNPI1770147357assigned 04/29/2019
33bProvider typePrimary Care Clinic/Center
28Total paid$2.18M
24GClaims39,542
24DCodes billed40
24AFirst – last monthSep 2019 – Dec 2024
Compared with peers
Next to other Primary Care Clinic/Center providers in Oregon
Rank by total paid#1 of 71
Median peer was paid$39K
This provider vs. median56×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 620 | $47K | |
| 2020 | 4,102 | $178K | |
| 2021 | 6,542 | $277K | |
| 2022 | 12,277 | $588K | |
| 2023 | 9,655 | $561K | |
| 2024incomplete | 6,346 | $525K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 36% | 8,113 | 7,170 | $782K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 14% | 2,323 | 2,102 | $299K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 13% | 3,403 | 3,037 | $284K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 13% | 4,265 | 3,767 | $277K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 7.6% | 1,281 | 1,083 | $166K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 6.5% | 551 | 474 | $141K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.0% | 1,656 | 1,477 | $65K |
| 99051 | <1% | 3,549 | 3,199 | $20K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 394 | 310 | $19K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 863 | 766 | $17K |
| S9088 | Services provided in an urgent care center (list in addition to code for service) | <1% | 5,545 | 4,976 | $17K |
| 87486 | <1% | 581 | 499 | $12K |
28 more codes
| 87581 | <1% | 566 | $12K | |
| 87640 | <1% | 529 | $10K | |
| 99072 | <1% | 3,205 | $9K | |
| 99441 | <1% | 201 | $7K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 298 | $7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 393 | $6K |
| 87481 | <1% | 268 | $5K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 84 | $4K |
| 99442 | <1% | 55 | $4K | |
| 87541 | <1% | 158 | $4K | |
| 87653 | <1% | 97 | $2K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 90 | $1K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 53 | $853.79 |
| 36415 | Collection of venous blood by venipuncture | <1% | 217 | $591.60 |
| 87529 | <1% | 14 | $554.36 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 60 | $534.37 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 29 | $522.78 |
| 81003 | <1% | 351 | $475.42 | |
| 87500 | <1% | 17 | $361.39 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 15 | $301.74 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 28 | $300.82 |
| 87563 | <1% | 14 | $277.18 | |
| 80053 | Comprehensive metabolic panel | <1% | 15 | $98.19 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 13 | $67.62 |
| 36416 | <1% | 18 | $56.70 | |
| 99000 | <1% | 196 | $15.56 | |
| 90694 | 0% | 17 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSANKAR, GURU (CENTER DIRECTOR)
Parent organizationUPTOWN PROVIDERS PC
| Provider | Location | Paid |
|---|---|---|
| Uptown Providers INC | Portland, OR | $2.78M |
| Uptown Providers PC | Beaverton, OR | $2.11M |
| Uptown Providers PC | Portland, OR | $1.01M |
| Uptown Providers PC | Hillsboro, OR | $656K |
| Uptown Providers PC | Tigard, OR | $636K |
| Uptown Providers PC | Lake Oswego, OR | $398K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.